Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Translational Research Business	108.20M	54.16M	13.23M	16.48M	12.86M
Translational Research Business Growth	99.77%	309.47%	-19.74%	28.13%	5.06%
CRO Business	31.28B	31.60B	25.91B	24.00B	17.05B
CRO Business Growth	-1.01%	21.94%	7.96%	40.78%	17.50%
Medipolis Business	804.31M	564.93M	569.08M	683.66M	563.50M
Medipolis Business Growth	42.37%	-0.73%	-16.76%	21.32%	2.05%
US Property Management Business	184.40M	45.98M	-	-	-
US Property Management Business Growth	301.05%	-	-	-	-
Other	1.97B	1.79B	1.41B	1.44B	968.97M
Other Growth	9.77%	27.21%	-2.09%	48.34%	92.31%
Unallocated Adjustments	-1.81B	-1.64B	-1.45B	-1.05B	-844.70M
Total	32.52B	32.41B	26.45B	25.09B	17.75B
Total Growth	0.34%	22.55%	5.42%	41.37%	17.46%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
United States of America	8.52B	6.37B	4.48B	3.84B	-
United States of America Growth	33.63%	42.18%	16.62%	-	-
Korea	1.59B	4.02B	3.76B	-	-
Korea Growth	-60.45%	6.79%	-	-	-
Japan	21.08B	21.52B	17.81B	18.52B	-
Japan Growth	-2.08%	20.84%	-3.80%	-	-
Others	1.34B	498.21M	393.21M	2.73B	-
Others Growth	169.63%	26.70%	-85.61%	-	-
Total	32.52B	32.41B	26.45B	25.09B	-
Total Growth	0.34%	22.55%	5.42%	-	-

Source: S&P Global Market Intelligence.